To compare both, the 5-d itch scale scores and the DLQI scores in patients with chronic plaque psoriasis with pruritus

Dr. Anuj Kothari and Dr. Simran Singh Aujla

DOI: https://doi.org/10.33545/26649411.2020.v3.i2b.50

Abstract

Background and Method: 80 patients of chronic plaque Psoriasis were evaluated under the study. Relevant history, clinical examination and necessary investigations along with PASI were done for all the patients. Severity of Pruritus was measured using the 5-D Itch scale. Quality of life of all chronic plaque psoriasis patients was evaluated by using Dermatology Life Quality Index (DLQI) structured questionnaire. It will be a prospective study in which patients will be selected randomly and the patients enrolled will be categorized under these.

Result: There is a significantly positive ($P<0.05$) correlation between 5-D Itch score and DLQI score, 5-D Itch score and PASI score as well as the DLQI and PASI score. The difference levels of DLQI and the 5-D Itch score was $p>0.05$ hence non-significant where as that of PASI with 5-D Itch score and DLQI respectively was $P<0.05$ hence significant. There is no significant difference in mean age of mild and severe pruritus patients.

Conclusion: We concluded, warranted in this context since our findings are not in keeping with previous literature suggesting pruritus affects mental health. Further, we observed that pruritus is associated with determinants to emotional well-being as measured by the DLQI and with detriments to other realms of mental health, including social functioning. Pruritus which may be underestimated & unaddressed in clinical practice at times, is a potentially serious and debilitating symptom that warrants medical attention and treatment, and further research investment.

Keywords: DLQI, plaque, psoriasis, pruritus

Introduction

Psoriasis is universal in occurrence. In United States psoriasis affects about 2% of the population with approximately 150,000 newly diagnosed cases per year. The worldwide incidence varies considerably [1]. Psoriasis is a genetically determined immune-mediated inflammatory disease mediated by T-helper 1 (Th1)/Th17 T cells. With a prevalence of 0.44-2.8 per cent in India, it commonly affects individuals in their third or fourth decade with males being affected two times more common than females1. Psoriasis significantly impairs the quality of life of patients and their families resulting in great physical, emotional and social burden [2]. Its prevalence varies from 0.3% or less in Mongoloids and more than 2% in Scandinavia. In both North America and Europe the prevalence has been estimated to be between 1% to 2%. In a recent community based study from U.K., a prevalence of 1.48% was found. The incidence of psoriasis ranges from 0.97% in South America to 1.3% in Germany, 1.6% in Great Britain, 1.7% in Denmark and 2.3% in Sweden [3]. Genetic factors play an important role in the pathogenesis of psoriasis. Based on population studies, the risk of psoriasis in an offspring has been estimated to be 41% if both the parents are affected, 14% if one of the parents is affected, and 6% if one sibling is affected, compared to 2% when no parent or sibling is affected. Concordance for psoriasis in monozygotic twins ranges from 35% to 73% in various studies. Despite multiple genome wide linkage studies, only 1 locus termed psoriasis susceptibility 1 (PSORS1) has been consistently confirmed [4]. PSORS1 is located in the major histocompatibility complex (MHC, chromosome 6p21.3) of HLA gene. Multiple HLA alleles have been associated with psoriasis, particularly HLA- B13, HLA- B37, HLA-B46,
HLA-B57, HLA-Cw1, HLA- Cw6, HLA-DR7 and HLA-DQ9.

Material and Method
The study was conducted from June 2019 to May 2020, a total of 80 patients with chronic plaque Psoriasis were evaluated under the study in the Department of Dermatology, Venereology and leprosy, American International Institute of Medical Sciences, Udaipur (Rajasthan).

Methods
80 patients of chronic plaque Psoriasis were evaluated under the study. Relevant history, clinical examination and necessary investigations along with PASI were done for all the patients. Severity of Pruritus was measured using the 5-D Itch scale. Quality of life of all chronic plaque psoriasis patients was evaluated by using Dermatology Life Quality Index (DLQI) structured questionnaire. It will be a prospective study in which patients will be selected randomly and the patients enrolled will be categorized under these.

Inclusion criteria
Arm 1: Patients with mild-moderate Pruritus
Arm 2: Patients with moderate-severe Pruritus

1. Patients with chronic plaque psoriasis between the age of 16-70yrs.
2. Chronic plaque psoriasis patient of both sexes were to be evaluated.
3. All newly diagnosed cases, as well as old cases of psoriasis with exacerbations were evaluated under study.
4. Chronic plaque psoriasis involving a minimum 5% body surface area.
5. Chronic plaque psoriasis-associated pruritus, defined as at least 2 episodes of itch per week, the itch occurring several times a day, lasting for more than 5 minutes, being bothersome, and had been present for a minimum of 6 weeks.

Exclusion criteria
1. All patient of psoriasis below 16 yrs. were excluded from the study.
2. All patients not having a minimum 5% BSA involvement.
3. All patients not having pruritus as an accompanying symptom
4. All psoriasis patients who were handicapped or having other chronic debilitating diseases or other associated chronic skin disorders were excluded from the study.

Results

| Correlation | 5-D ITCH scale R (P-value) | DLQI score R (P-value) | PASI score R (P-value) |
|-------------|-----------------------------|------------------------|------------------------|
| 5-D Itch Scale | 1 | 0.939 (0.0001) | 0.881 (0.0001) |
| DLQI Score | 0.939 (0.0001) | 1 | 0.899 (0.0001) |
| PASI Score | 0.881 (0.0001) | 0.899 (0.0001) | 1 |
| N | 80 | 80 | 80 |

There is a significantly positive (P<0.05) correlation between 5-D Itch score and DLQI score, 5-D Itch score and PASI score as well as the DLQI and PASI score.

| Differences of levels | T-value | P-value |
|-----------------------|---------|---------|
| DLQI Score - 5-D Itch Score | -1.95 | 0.128 |
| PASI - 5-D Itch score | 5.20 | 0.000 |
| PASI - DLQI Score | 7.15 | 0.000 |

The difference levels of DLQI and the 5-D Itch score was p>0.05 hence non-significant where as that of PASI with 5-D Itch score and DLQI respectively was P<0.05 hence significant.

Table 1: Correlation matrix in study group

There is no significant difference in mean age of mild and severe pruritus patients

Discussion
Out of 80 patients, psoriasis associated pruritus had small effect on quality of life in 37.5% of the patients, moderate effect on 15% of patients and severe effect on 47.5% of patients. So Psoriasis with associated pruritus affected the QOL in 100% of the patients.

The mean DLQI score was significantly higher in the moderate-severe pruritus group than in the mild-moderate pruritus cases. Increase in the 5-d Itch scale score was associated with increased effect on quality of life.

The mean DLQI score was significantly higher in the moderate-severe pruritus group than in the mild-moderate pruritus group. The mean difference between the two groups remained significant (P<0.0001).

Conclusion
We concluded, warranted in this context since our findings are not in keeping with previous literature suggesting pruritus affects mental health. Further, we observed that pruritus is associated with determinants to emotional well-being as measured by the DLQI and with detrimental to other realms of mental health, including social functioning. Pruritus which may be underestimated & unaddressed in clinical practice at times, is a potentially serious and debilitating symptom that warrants medical attention and treatment, and further research investment.
References

1. Chalmers RJG, Psoriasis. In: Williams H, Bigby M, Diepgen T, Hercheimer A, Naldi L, Rjancy B, editors. evidence based Dermatology: London: BMJ publishing group 2003, P226-252.

2. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010;76:595-601.

3. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Text book of Dermatology: 6th edn vol 2, London: Blackwell science 1998, P1589-1649.

4. White SH, Newcomer VD, Mickey MR, Terasaki PI: Disturbance of HL-A antigen frequency in psoriasis. N Engl J Med 1972;287:740-743.

5. Johann Gudjonsson E, James Elder Psoriasis T. In Klaus Wolff, Lowella A. Goldsmith, Stephen I Katz, Barbara A, Gilchrest Amy S. Paller, David J Leffel editors. Fitzpatrick Dermatology in General Medicine: 7th edition; vol. 1, Newyork: McGraw. Hill, 2008, P169-193.

6. Sampogna F, Picardi A, Melchi CF, Pasquini P, Abeni D: The impact of skin disease on patients: Comparing dermatologist opinion with research data collected on their patients. Br J Dermatol 2003;148:989-995.

7. Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G: Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 2000;95:497-502.

8. Duque MI, Yosipovitch G, Chan YH, Smith R, Levy P. Itch, pain and burning sensation are common symptoms in mild-moderate chronic venous insufficiency with an impact on quality of life. J Am Acad Dermatol 2005;53:504-508.

9. Moloney FJ, Keane S, O’Kelly P, Conlon PJ, Murphy GM: The impact of skin disease following renal transplantation on quality of life. Br J Dermatol 2005;153:574-578.